|

Plerixafor Clinical Trials

5 actively recruiting trials across 5 locations

Also known as: AMD 3100, LM-3100, Mobozil, Mozobil

Stanford, California1 trial

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Stanford University

Phase 1

Bethesda, Maryland1 trial

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

National Institutes of Health Clinical Center

Phase 1/2

St Louis, Missouri1 trial

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Washington University School of Medicine

Phase 1/2

Philadelphia, Pennsylvania1 trial

Mozobil for Autologous Hematopoietic Stem Cell Transplantation

Thomas Jefferson University Hospital

Phase 2

Houston, Texas1 trial

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.